MK-2866, commonly known as Ostarine, is a non-steroidal selective androgen receptor modulator developed to selectively bind to androgen receptors in muscle and skeletal tissue. Research indicates MK-2866 may promote lean muscle mass, enhance strength, and improve bone density while minimizing the side effects associated with traditional anabolic agents.
Preclinical and early clinical investigations suggest Ostarine may have applications in muscle wasting conditions, age-related sarcopenia, and osteoporosis. Its high oral bioavailability and tissue selectivity make it a valuable compound for advancing research in regenerative medicine, performance enhancement, and metabolic health.
